BioAtla, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BCAB, updated each market day.
BCAB AI Sentiment
AI predicts BioAtla, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About BioAtla, Inc. Common Stock
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Sector
Exchange
Market Cap
$7,489,305
Cap Tier
Employees
41
Headquarters
SAN DIEGO, CA
Listed Since
Dec. 16, 2020
Website
BCAB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BCAB Volatility
BioAtla, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
